Royalty Pharma Price to Free Cash Flow Ratio 2019-2024 | RPRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Royalty Pharma average price to free cash flow ratio for 2024 was 7.03, a 19.97% increase from 2023.
Royalty Pharma average price to free cash flow ratio for 2023 was 5.86, a 20.16% increase from 2022.
Royalty Pharma average price to free cash flow ratio for 2022 was 7.34, a 263.37% decline from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Royalty Pharma average price to free cash flow ratio for 2024 was 7.03, a 19.97% increase from 2023.
Royalty Pharma average price to free cash flow ratio for 2023 was 5.86, a 20.16% increase from 2022.
Royalty Pharma average price to free cash flow ratio for 2022 was 7.34, a 263.37% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
American Express (AXP)	$222.1B
Blackstone (BX)	$133.8B
Moody's (MCO)	$88.8B
Brookfield Asset Management (BAM)	$27.2B
Synchrony Financial (SYF)	$26.8B
Orix Corp Ads (IX)	$24.7B
SoFi Technologies (SOFI)	$17.4B
Equitable Holdings (EQH)	$17B
Jefferies Financial Group (JEF)	$15.6B
BB Seguridade Participacoes SA (BBSEY)	$13.3B
Houlihan Lokey (HLI)	$12.5B
Globe Life (GL)	$10.2B
Daiwa Securities Group (DSEEY)	$9.6B
Brookfield Wealth Solutions (BNT)	$8.8B
Freedom Holding (FRHC)	$8.5B
SouthState (SSB)	$8.1B
StepStone Group (STEP)	$7.4B
XP (XP)	$7.3B
Virtu Financial (VIRT)	$6.1B
Upstart Holdings (UPST)	$6B
Lazard (LAZ)	$5.9B
Rithm Capital (RITM)	$5.9B
Blue Owl Capital (OBDC)	$5.8B
Euronet Worldwide (EEFT)	$4.3B
AXOS FINANCIAL, INC (AX)	$4B
PJT Partners (PJT)	$3.9B
StoneX Group (SNEX)	$3.5B
Abrdn (SLFPY)	$3.5B
Community Financial System (CBU)	$3.4B
Intercorp Financial Services (IFS)	$3.4B